National Institutes of Health to Evaluate Berg’s Drug for the Treatment of Kidney Cancer
BOSTON, Sept. 8, 2015 — Berg, a Boston-based biopharmaceutical company, has announced that it has entered into a Materials-Cooperative Research and Development Agreement (M-CRADA) with the United States National Institutes of Health (NIH) for the treatment of kidney cancer. Dr. W. Marston Linehan, Chief of Urologic Oncology at the Center for Cancer Research at the National Cancer Institute (NCI) will conduct a preclinical evaluation of Berg’s drug BPM 31510.
Berg, the namesake of Chairman and Co-founder, Carl E. Berg with Co-Founders Niven R. Narain, President & CTO and Mitch Gray, Managing Director, is a leading precision medicine company merging biology with Bayesian AI to fundamentally understand patient populations as a foundation to create the next generation of drugs and diagnostics. Berg harnesses the power of technology to allow a patient’s own biology to inform the direction of that patient’s care.
“We are extremely focused on strategic alliances around BPM 31510 as we plan for Phase II trials. We anticipate that Dr. Linehan’s team will be instrumental in helping us understand the potential use of BPM 31510 in kidney cancer,” said Niven R. Narain, Co-Founder, President & CTO.
BPM 31510 is one of the first drugs to be guided by artificial intelligence. It works by reversing the Warburg effect, and targets the energy source of the cancer cell itself. It has shown clinical benefits and anti-cancer effects in multiple cancer types in an on-going Phase Ib trial.
Additional Berg collaborations include the U.S. Department of Defense, Parkinson’s Institute, Harvard Medical School, M.D. Anderson, Weill Cornell Medical Center, Cancer Research And Biostatistics (CRAB)®/Pancreatic Cancer Research Team, and more.
To learn more about Berg, please visit www.berghealth.com.
Berg, is a biopharmaceutical company with divisions that include Analytics, Pharma, Biosystems and Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of preclinical assets in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemo-toxicity. Armed with the use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, please visit www.berghealth.com.
About the Berg Interrogative Biology® Platform
Berg’s application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.